ENGN (enGene Therapeutics) Beginning Cash Position: $36.61 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENGN enGene Therapeutics Inc ENGN
12 GF Score
Price $1.72
! 1 Warning Sign
View Full Analysis

What is enGene Therapeutics Beginning Cash Position?

enGene Therapeutics ENGN +1.78% 12 Beginning Cash Position is $36.61 Mil as of Apr. 2026. GuruFocus rates ENGN with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

enGene Therapeutics's Beginning Cash Position for the quarter that ended in Apr. 2026 was $36.61 Mil.

enGene Therapeutics's quarterly Beginning Cash Position increased from Oct. 2025 ($32.62 Mil) to Jan. 2026 ($50.15 Mil) but then declined from Jan. 2026 ($50.15 Mil) to Apr. 2026 ($36.61 Mil).

enGene Therapeutics's annual Beginning Cash Position increased from Oct. 2023 ($20.43 Mil) to Oct. 2024 ($81.52 Mil) and increased from Oct. 2024 ($81.52 Mil) to Oct. 2025 ($173.00 Mil).

enGene Therapeutics Beginning Cash Position Related Terms

enGene Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for enGene Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

enGene Therapeutics Beginning Cash Position Chart

enGene Therapeutics Annual Data
Trend Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Beginning Cash Position
Get a 7-Day Free Trial 4.63 11.02 20.43 81.52 173.00

enGene Therapeutics Quarterly Data
Oct21 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.35 57.55 32.62 50.15 36.61
ENGN
12GF Score
enGene Therapeutics Inc ENGN
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

enGene Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $36.61 Mil mean?
enGene Therapeutics (ENGN) has a Beginning Cash Position of $36.61 Mil as of Apr. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on enGene Therapeutics and its competitors.
Is enGene Therapeutics' Beginning Cash Position too high?
enGene Therapeutics' current Beginning Cash Position is $36.61 Mil. Overall, enGene Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' Beginning Cash Position compare to VTVT and GUTS?
enGene Therapeutics' Beginning Cash Position of $36.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on enGene Therapeutics and its competitors. enGene Therapeutics's current Beginning Cash Position is $36.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (ENGN) has a current Beginning Cash Position of $36.61 Mil. The current Beginning Cash Position is $36.61 Mil. enGene Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For enGene Therapeutics (ENGN), the current Beginning Cash Position is $36.61 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

enGene Therapeutics Business Description

Other Exchanges S0N0:Germany
Address 4868 Rue Levy, Suite 220, Saint-Laurent, QC, CAN, H4R 2P1
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
12GF Score

Get the complete analysis for ENGN

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price